Alzheimer Europe

*Making dementia a priority:*
*changing perceptions, practice and policy.*

# CLINICAL TRIALS WATCH

## ACCESSIBLE EASY READ INFORMATION ON:

# GSK4527226 STUDY

**Alzheimer Europe** • R.C.S. LUXEMBOURG F2773 • 5 Heienhaff, L-1736 Senningerberg
Tel. +352 29 79 70 • Fax +352 29 79 72 • info@alzheimer-europe.org • www.alzheimer-europe.org

# GSK4527226 study

| 1. Study Information | |
|---|---|
| **Name of the study** | Open-label extension study in participants with early Alzheimer's disease |
| **Study sponsor** | GlaxoSmithKline |
| **Disease** | Early Alzheimer's disease |
| **Phase** | Phase II - Open Label Extension study |

| 2. Information about the drug that will be tested in the study | |
|---|---|
| **Name of drug** | GSK4527226 |
| **Administration** | The drug will be administered via an intravenous infusion (an injection into the vein). |
| **Is the drug already on the market for another medical condition?** | No |
| **Will all participants receive the same drug?** | All participants will receive GSK4527226. |

| 3. Information about participating in the trial | |
|---|---|
| **What are the researchers trying to find out?** | • The purpose of the study is to evaluate the long-term safety and efficacy of GSK4527226 in people with early Alzheimer's disease (including mild cognitive impairment and mild dementia due to Alzheimer's disease) who have completed the PROGRESS-AD study. |
| **How long will the treatment last?** | • Around 2 years. |
| **What your involvement will entail?** | • During the study, participants will be asked to complete tests that will assess their cognition, function, memory and activities of daily living (i.e. CDR-SB, iADRS, ADAS-Cog14, ADCS-iADL, ADCOMS)<br>• Participants will undergo brain scans (MRI)<br>• Complete some laboratory tests to evaluate the emergent adverse events (unfavourable signs, symptoms or diseases |

| | |
|---|---|
| | temporally associated with the use of the drug tested in the study).<br><br>Further information on the procedures, tests and number of visits can be obtained from the study team. |

| 4. Who can participate in this study? | |
|---|---|
| **Who can participate in the study?** | To take part in the study, participants must:<br><br>• Be between 50 and 85 years old<br><br>• Have completed the parent study named PROGRESS-AD<br><br>• Have a study partner who has a sufficient contact with the participant, is willing to participate in study procedures throughout the study duration and report on cognitive and functional abilities<br><br>• For female participants: not be pregnant or breastfeeding<br><br>• Use contraception. |
| **Who cannot participate in the study?** | Exclusion criteria include:<br><br>• Evidence of any Amyloid related imaging abnormalities (ARIA) or cerebral macrohemorrhage<br><br>• A disease or condition that may interfere with the safety, tolerability and/or study assessments<br><br>• Newly identified conditions or diseases such as infection(s) that may affect the central nervous system, diagnosed cancer, genetic predisposition for clotting disorder or hemorrhagic disease<br><br>• Severe alcohol and/or substance use disorder. |

| | |
|---|---|
| | The above list is not exhaustive. It includes the most common conditions and diseases that might exclude people from the study. |

| 5. Where and when will the study be conducted? | |
|---|---|
| **European countries involved in the trial (active)** | • Finland<br>• France<br>• Germany<br>• Norway<br>• Spain<br>• Sweden<br>• UK |
| **European countries that will be involved in the trial (planned)** | • Italy<br>• Netherlands |
| **Estimated start date of recruitment** | November 2025 |

| 6. Information for your doctor | | | |
|---|---|---|---|
| **Clinicaltrials.gov identifier** | NCT07105709 | **EU CT Number** | 2025-521107-42-00 |
| **Study contact information** | GSKClinicalSupportHD@gsk.com | | |
| **Link to full text** | https://clinicaltrials.gov/study/NCT07105709<br><br>https://euclinicaltrials.eu/ctis-public/view/2025-521107-42-00 | | |

✓ The information contained in this document is based on information available on public registries (e.g. clinicaltrials.gov, CTIS websites) in April 2026.